{"id":19098,"date":"2024-12-20T22:20:09","date_gmt":"2024-12-20T14:20:09","guid":{"rendered":"https:\/\/flcube.com\/?p=19098"},"modified":"2024-12-20T22:20:11","modified_gmt":"2024-12-20T14:20:11","slug":"boston-scientifics-next-gen-ivus-system-avvigo-approved-by-chinas-nmpa-for-coronary-disease-use","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19098","title":{"rendered":"Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use"},"content":{"rendered":"\n

US-based Boston Scientific Corporation (NYSE: BSX<\/a>) has announced that China’s National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China.<\/p>\n\n\n\n

Multimodal Platform with AI Capabilities<\/strong>
The AVVIGO+ system is a multimodal platform that integrates advanced imaging and functionality. Equipped with artificial intelligence (AI) capabilities, the IVUS system includes the Auxiliary Vascular Assessment (ALA) function, which can automatically execute key steps and deliver intuitive and precise vascular measurement data. This innovation significantly reduces operation time, enhancing the efficiency of medical procedures.<\/p>\n\n\n\n

AI-Assisted Vascular Assessment Streamlines PCI Treatment<\/strong>
Furthermore, the system features AI-assisted vascular assessment, empowering physicians to optimize the evaluation process during percutaneous coronary intervention (PCI) treatment. By streamlining the operational workflow, the AVVIGO+ system contributes to shorter procedure times, which is crucial in a clinical setting.<\/p>\n\n\n\n

Global Success and Market Expansion<\/strong>
The device has already found success in Europe and the US, where it received clearance for use. The NMPA’s approval in China is expected to further expand the reach of this innovative technology, offering Chinese patients access to a leading-edge diagnostic tool for coronary heart disease.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA)…<\/p>\n","protected":false},"author":1,"featured_media":19099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[99,315,1160,15],"class_list":["post-19098","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-ai","tag-boston-scientific","tag-nyse-bsx","tag-product-approvals"],"yoast_head":"\nBoston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Boston Scientific Corporation (NYSE: BSX) has announced that China's National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19098\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use\" \/>\n<meta property=\"og:description\" content=\"US-based Boston Scientific Corporation (NYSE: BSX) has announced that China's National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19098\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-20T14:20:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-20T14:20:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2005-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"637\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use\",\"datePublished\":\"2024-12-20T14:20:09+00:00\",\"dateModified\":\"2024-12-20T14:20:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098\"},\"wordCount\":227,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2005-1.png\",\"keywords\":[\"AI\",\"Boston Scientific\",\"NYSE: BSX\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19098#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19098\",\"name\":\"Boston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2005-1.png\",\"datePublished\":\"2024-12-20T14:20:09+00:00\",\"dateModified\":\"2024-12-20T14:20:11+00:00\",\"description\":\"US-based Boston Scientific Corporation (NYSE: BSX) has announced that China's National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19098\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2005-1.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2005-1.png\",\"width\":1080,\"height\":637,\"caption\":\"Boston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19098#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use - Insight, China's Pharmaceutical Industry","description":"US-based Boston Scientific Corporation (NYSE: BSX) has announced that China's National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19098","og_locale":"en_US","og_type":"article","og_title":"Boston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use","og_description":"US-based Boston Scientific Corporation (NYSE: BSX) has announced that China's National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China.","og_url":"https:\/\/flcube.com\/?p=19098","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-20T14:20:09+00:00","article_modified_time":"2024-12-20T14:20:11+00:00","og_image":[{"width":1080,"height":637,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2005-1.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19098#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19098"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use","datePublished":"2024-12-20T14:20:09+00:00","dateModified":"2024-12-20T14:20:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19098"},"wordCount":227,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19098#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2005-1.png","keywords":["AI","Boston Scientific","NYSE: BSX","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19098#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19098","url":"https:\/\/flcube.com\/?p=19098","name":"Boston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19098#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19098#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2005-1.png","datePublished":"2024-12-20T14:20:09+00:00","dateModified":"2024-12-20T14:20:11+00:00","description":"US-based Boston Scientific Corporation (NYSE: BSX) has announced that China's National Medical Products Administration (NMPA) has granted approval for its next-generation intravascular ultrasound (IVUS) diagnostic system, AVVIGO+, for use in diagnosing coronary heart disease. This marks a significant advancement in the diagnostic capabilities for cardiovascular healthcare in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19098#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19098"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19098#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2005-1.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2005-1.png","width":1080,"height":637,"caption":"Boston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19098#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2005-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19098"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19098\/revisions"}],"predecessor-version":[{"id":19100,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19098\/revisions\/19100"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19099"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}